The vision of the Herbert Irving Comprehensive Cancer Center (HICCC) is that discoveries here will end cancer everywhere. This is achieved through a dynamic, multi-pronged mission: (1) foster discovery science, (2) translate discovery science into innovative clinical trials and interdisciplinary clinical care, and (3) promote bidirectional community outreach and engagement, all of which is promulgated through a Strategic Plan. The goals of Leadership, Planning, and Evaluation (LPE) are to create and sustain this vision by nurturing an innovative and nimble leadership team, buttressed by internal and external advisory groups, and inclusion of the HICCC membership for the identification and prioritization of new opportunities. The HICCC furthermore charges its leadership and advisory bodies to develop and maintain the Strategic Plan, which interdigitates with the institutional Strategic Plan. Leading the HICCC?s leadership, planning and evaluation activities is the Director, Anil K. Rustgi, MD, a nationally known translational researcher who was recruited last year from the University of Pennsylvania?s Abramson Cancer Center. Rustgi is supported by a highly experienced and cohesive team of Senior Leadership that includes a Deputy Director and six Associate Directors. Together, this team comprises the Senior Leadership Team (SLT). The SLT actively engages Program Leaders and a core of internal advisors in strategy and decision making through Cancer Center Leadership Team (CCLT) meetings, where strategic and operational matters are discussed and recommendations made to the Center Director. A highly productive committee structure, which includes an Internal Advisory Board (IAB), External Advisory Board (EAB), Community Advisory Board (CAB), and Cancer Research Career Enhancement (CRCE) Committee, complements HICCC leadership and allows for diverse perspectives to help shape and guide the future of the HICCC. Under Rustgi, the HICCC has set forth a new vision, which will help realize the Cancer Center?s full potential over the next project period and beyond. Concurrently, care was taken to ensure that the HICCC continuously responds to the CCSG Summary Statement, changing expectations for NCI-designated Comprehensive Cancer Centers, and ongoing feedback and guidance from the IAB, EAB, CAB, and others. All contributors have enthusiastically endorsed the Strategic Plan, along with the initiatives that have been identified for the years ahead. The current LPE, which is hallmarked by active listening, inclusion, and an unyielding commitment to serving the community, has resulted in a time of unprecedented growth. This is evidenced throughout the application in the accomplishments and plans for Research Programs, COE, Shared Resources, and CRCE, including noteworthy accomplishments in translation by bringing HICCC discoveries into the clinic.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Center Core Grants (P30)
Project #
2P30CA013696-45
Application #
10022780
Study Section
Subcommittee I - Transistion to Independence (NCI)
Project Start
1997-07-04
Project End
2025-06-30
Budget Start
2020-07-01
Budget End
2021-06-30
Support Year
45
Fiscal Year
2020
Total Cost
Indirect Cost
Name
Columbia University (N.Y.)
Department
Type
DUNS #
621889815
City
New York
State
NY
Country
United States
Zip Code
10032
Jauregui, Ruben; Thomas, Amanda L; Liechty, Benjamin et al. (2018) SCAPER-associated nonsyndromic autosomal recessive retinitis pigmentosa. Am J Med Genet A :
Ghorpade, Devram S; Ozcan, Lale; Zheng, Ze et al. (2018) Hepatocyte-secreted DPP4 in obesity promotes adipose inflammation and insulin resistance. Nature 555:673-677
Bianchetti, E; Bates, S J; Carroll, S L et al. (2018) Usp9X Regulates Cell Death in Malignant Peripheral Nerve Sheath Tumors. Sci Rep 8:17390
Jauregui, Ruben; Park, Karen Sophia; Duong, Jimmy K et al. (2018) Quantitative Comparison of Near-infrared Versus Short-wave Autofluorescence Imaging in Monitoring Progression of Retinitis Pigmentosa. Am J Ophthalmol 194:120-125
Proto, Jonathan D; Doran, Amanda C; Subramanian, Manikandan et al. (2018) Hypercholesterolemia induces T cell expansion in humanized immune mice. J Clin Invest 128:2370-2375
Shang, Enyuan; Zhang, Yiru; Shu, Chang et al. (2018) Dual Inhibition of Bcl-2/Bcl-xL and XPO1 is synthetically lethal in glioblastoma model systems. Sci Rep 8:15383
Shen, Megan Johnson; Prigerson, Holly G; Ratshikana-Moloko, Mpho et al. (2018) Illness Understanding and End-of-Life Care Communication and Preferences for Patients With Advanced Cancer in South Africa. J Glob Oncol :1-9
Apatoff, Mary Ben L; Sengillo, Jesse D; White, Eugenia C et al. (2018) Autologous stem cell therapy for inherited and acquired retinal disease. Regen Med 13:89-96
Billing, David; Horiguchi, Michiko; Wu-Baer, Foon et al. (2018) The BRCT Domains of the BRCA1 and BARD1 Tumor Suppressors Differentially Regulate Homology-Directed Repair and Stalled Fork Protection. Mol Cell 72:127-139.e8
Connors, Thomas J; Baird, J Scott; Yopes, Margot C et al. (2018) Developmental Regulation of Effector and Resident Memory T Cell Generation during Pediatric Viral Respiratory Tract Infection. J Immunol 201:432-439

Showing the most recent 10 out of 331 publications